KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. They are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, they continuously expand and improve their technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.
Funding Rounds (1) - undisclosedUpdate
Board Members and Advisors (1)Update
|Oct 15, 2013||evotec.com - Evotec - Creating integrated drug discovery innovation alliances|
|May 9, 2007||PE HUB - PE HUB|
Am Klopferspitz 19a